Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector - PubMed (original) (raw)
Review
. 1999 Sep 20;18(38):5268-77.
doi: 10.1038/sj.onc.1202997.
Affiliations
- PMID: 10498879
- DOI: 10.1038/sj.onc.1202997
Review
Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector
J M Adams et al. Oncogene. 1999.
Abstract
The pathways to lymphoid neoplasia have been explored in a number of transgenic models. Because B lymphoid malignancies often involve translocation of an oncogene (e.g. myc, bcl-2, cyclin D1) to an immunoglobulin locus, resulting in its deregulated expression, the consequences of oncogene overexpression in lymphocytes can be evaluated with transgenes driven by an immunoglobulin regulatory element, such as an enhancer from the IgH locus. Mice bearing such transgenes have provided insight into the preneoplastic state, including alterations in the control of cellular proliferation, differentiation or apoptosis. They have also allowed studies on oncogene cooperation in vivo and the modulating effect of genetic background. Briefly reviewed here are the models studied in the authors' laboratories. Mice bearing myc and bcl-2 transgenes have received most attention but others studied include abl, ras, cyclin D1 and bmi-1 oncogenes. Also discussed is a new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias. The vector bears elements from the promoter region of the vav gene, which is expressed almost exclusively in hematopoietic cells. It has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. This novel vector should aid studies on many aspects of hematopoiesis, including the modeling of leukemogenesis.
Similar articles
- The transgenic window on lymphoid malignancy.
Adams JM, Harris AW, Vaux DL, Alexander WS, Rosenbaum H, Klinken SP, Strasser A, Bath ML, McNeall J, Cory S. Adams JM, et al. Princess Takamatsu Symp. 1989;20:297-309. Princess Takamatsu Symp. 1989. PMID: 2518688 - Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A, Harris AW, Bath ML, Cory S. Strasser A, et al. Nature. 1990 Nov 22;348(6299):331-3. doi: 10.1038/348331a0. Nature. 1990. PMID: 2250704 - Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice.
Almarza E, Segovia JC, Guenechea G, Gómez SG, Ramírez A, Bueren JA. Almarza E, et al. Exp Hematol. 2004 Apr;32(4):360-4. doi: 10.1016/j.exphem.2004.01.005. Exp Hematol. 2004. PMID: 15050746 - Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M, Lisowski L, Samakoglu S, Rivella S, May C, Riviere I. Sadelain M, et al. Ann N Y Acad Sci. 2005;1054:78-91. doi: 10.1196/annals.1345.010. Ann N Y Acad Sci. 2005. PMID: 16339654 Review. - Uncovering MYC's full oncogenic potential in the hematopoietic system.
Janz S. Janz S. Oncogene. 2005 May 19;24(22):3541-3. doi: 10.1038/sj.onc.1208473. Oncogene. 2005. PMID: 15782131 Review.
Cited by
- Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene.
Odaira K, Yasuda T, Okada K, Shimooka T, Kojima Y, Noura M, Tamura S, Kurahashi S, Iwamoto E, Sanada M, Matsumura I, Miyazaki Y, Kojima T, Kiyoi H, Tsuzuki S, Hayakawa F. Odaira K, et al. Cancer Sci. 2023 Mar;114(3):781-792. doi: 10.1111/cas.15641. Epub 2022 Nov 27. Cancer Sci. 2023. PMID: 36341510 Free PMC article. - Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead.
Sun M, Zhang H. Sun M, et al. Heliyon. 2019 Mar 7;5(3):e01297. doi: 10.1016/j.heliyon.2019.e01297. eCollection 2019 Mar. Heliyon. 2019. PMID: 31016256 Free PMC article. Review. - Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
Zhang H, Chen Z, Miranda RN, Medeiros LJ, McCarty N. Zhang H, et al. Blood. 2017 Aug 10;130(6):763-776. doi: 10.1182/blood-2017-02-767293. Epub 2017 Jun 7. Blood. 2017. PMID: 28592433 Free PMC article. - PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.
Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H. Hu C, et al. Sci Rep. 2017 Jun 6;7(1):2894. doi: 10.1038/s41598-017-03058-4. Sci Rep. 2017. PMID: 28588271 Free PMC article. - ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z, Teo AE, McCarty N. Chen Z, et al. Clin Cancer Res. 2016 Jan 1;22(1):187-99. doi: 10.1158/1078-0432.CCR-15-0987. Epub 2015 Sep 8. Clin Cancer Res. 2016. PMID: 26350264 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous